UBS Group’s Burning Rock Biotech BNR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $303K | Sell |
17,214
-702
| -4% | -$7.76K | ﹤0.01% | 6489 |
|
|
2026
Q2 | $150K | Buy |
17,916
+17,508
| +4,291% | +$248K | ﹤0.01% | 6963 |
|
|
2026
Q1 | $6.58K | Sell |
408
-760
| -65% | -$19.9K | ﹤0.01% | 8675 |
|
|
2025
Q4 | $23.5K | Buy |
1,168
+300
| +35% | +$4.38K | ﹤0.01% | 7676 |
|
|
2025
Q3 | $7.51K | Buy |
868
+159
| +22% | +$1.14K | ﹤0.01% | 8718 |
|
|
2025
Q2 | $2.24K | Buy |
709
+599
| +545% | +$1.86K | ﹤0.01% | 9496 |
|
|
2025
Q1 | $495 | Sell |
110
-1,320
| -92% | -$8.24K | ﹤0.01% | 9758 |
|
|
2024
Q4 | $9.7K | Sell |
1,430
-2,815
| -66% | -$13K | ﹤0.01% | 8347 |
|
|
2024
Q3 | $13.9K | Buy |
4,245
+1,665
| +65% | +$9.18K | ﹤0.01% | 7564 |
|
|
2024
Q2 | $16.6K | Buy |
2,580
+2,572
| +32,150% | +$19.6K | ﹤0.01% | 7424 |
|
|
2024
Q1 | $60 | Buy |
+8
| New | +$67 | ﹤0.01% | 8904 |
|
|
2023
Q4 | – | Sell |
-173
| Closed | -$1.67K | – | 9329 |
|
|
2023
Q3 | $1.67K | Buy |
+173
| New | +$2.7K | ﹤0.01% | 7858 |
|
|
2023
Q2 | – | Sell |
-292
| Closed | -$8.19K | – | 8949 |
|
|
2023
Q1 | $8.19K | Buy |
292
+105
| +56% | +$3.15K | ﹤0.01% | 7747 |
|
|
2022
Q4 | $4.22K | Buy |
+187
| New | +$4.26K | ﹤0.01% | 9362 |
|
|
2022
Q3 | – | Sell |
-3,172
| Closed | -$93K | – | 10342 |
|
|
2022
Q2 | $93K | Buy |
3,172
+2,922
| +1,169% | +$130K | ﹤0.01% | 5477 |
|
|
2022
Q1 | $23K | Buy |
250
+114
| +84% | +$9.9K | ﹤0.01% | 7281 |
|
|
2021
Q4 | $13K | Sell |
136
-7,460
| -98% | -$1.02M | ﹤0.01% | 8436 |
|
|
2021
Q3 | $1.36M | Buy |
7,596
+591
| +8% | +$131K | ﹤0.01% | 3918 |
|
|
2021
Q2 | $2.06M | Buy |
+7,005
| New | +$2.07M | ﹤0.01% | 3550 |
|
|
2021
Q1 | – | Sell |
-41
| Closed | -$9K | – | 9010 |
|
|
2020
Q4 | $9K | Buy |
+41
| New | +$11K | ﹤0.01% | 7551 |
|
|
2020
Q3 | – | Sell |
-329
| Closed | -$89K | – | 7988 |
|
|
2020
Q2 | $89K | Buy |
+329
| New | +$90.2K | ﹤0.01% | 5388 |
|
Other funds holding BNR
UBS Group's BNR Position: Q3 2026 in Review
UBS Group reduced its Burning Rock Biotech (BNR) stake by 3.9% in Q3 2026, selling an estimated $7.76K and leaving 17,214 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #6489.
UBS Group first reported a position in BNR in Q2 2020 and has held it in 21 quarters since. The position peaked at $2.06M in Q2 2021. 5 funds tracked by Wall St. Rank hold BNR as of Q3 2026.
- UBS Group held 17,214 shares of Burning Rock Biotech worth $303K as of Q3 2026.
- UBS Group sold 702 Burning Rock Biotech shares in Q3 2026, an estimated $7.76K.
- Burning Rock Biotech made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6489 holding.
- UBS Group first reported a position in Burning Rock Biotech in Q2 2020 and has held it in 21 quarters since.
- UBS Group's Burning Rock Biotech position peaked at $2.06M in Q2 2021.
- 5 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.